Welcome — and thank you for being one of the first people to open this. I started BH Leadership Brief for a simple reason: I wanted one quick, easy to read place that pulled together everything new in behavioral health that actually touches my job — and left out everything that doesn't. I spend my days as a leader on the inpatient psych side of behavioral healthcare, where a CMS rule change, a payer's prior-auth shift, or an unfilled psychiatrist line isn't theoretical — it directly shapes my everyday decision making. This is the read I always wanted: one place that pulls the federal and Colorado policy moves, the clinical and pharmacological developments, the technology and AI shifts, and the workforce signals worth knowing, and quietly skips the rest. No filler, no explaining your own job back to you — just the week's intelligence, sorted by what it changes for your operation, in about ten minutes. I'm glad you're here. Let's get into it.

CMS sets binding standards for Medicaid work requirements. On June 1, CMS issued an Interim Final Rule with comment period establishing binding standards for how states must implement Medicaid community engagement (“work”) requirements.

Implication: Watch eligibility churn — coverage interruptions feed uninsured admissions and uncompensated care on your inpatient units. CMS-relevant; track your state’s implementation timeline.

Colorado lands a CCBHC Medicaid demonstration slot. HCPF and the BHA announced June 1 that Colorado was selected into the CCBHC Demonstration Program, framed as strengthening the safety net and care coordination statewide.

Implication: CCBHC economics reshape downstream referral and step-down partners; if you discharge into CMHC/CCBHC settings, the reimbursement structure around you is shifting. Colorado BHA-relevant.

SAMHSA opens $40M across eight grant programs. On June 11, HHS announced $40 million in funding opportunities for eight grant programs under the Great American Recovery Initiative, spanning addiction prevention, workforce, and suicide prevention.

Implication: Discretionary grant access amid the broader SAMHSA reorganization — if you’ve had grant-funded programs in limbo, this is a live cycle.

Behavioral Health & Community Safety Partnerships NOFO posted. SAMHSA’s BH-CSP funding opportunity (SM-26-023) posted June 11 with an application due date of July 13, 2026.

Implication: Relevant if you operate or partner on co-responder or crisis-diversion lines feeding your front door.

FDA expands Caplyta to relapse prevention in schizophrenia. The FDA approved a supplemental NDA for lumateperone (Caplyta) for prevention of relapse, with trial data showing a 63% lower relapse risk versus placebo and 84% of participants relapse-free over six months, with a weight-neutral tolerability profile.

Implication: A discharge-and-maintenance lever — a tolerability-favorable maintenance option changes how you hand off stabilized schizophrenia patients to step-down.

Bysanti (milsaperidone) nears commercial availability. Vanda’s new atypical antipsychotic, approved in February for bipolar I and schizophrenia, is anticipated to reach commercial availability in Q3 2026; it converts to iloperidone in vivo, so its safety profile tracks a well-characterized agent.

Implication: A new NCE entering formulary conversations this quarter — worth a P&T heads-up now, not in Q3.

Teva’s once-monthly subcutaneous olanzapine LAI advances. The FDA accepted Teva’s NDA for olanzapine extended-release injectable suspension (TEV-’749) for adults with schizophrenia.

Implication: A long-acting olanzapine option speaks directly to the adherence gap that drives readmissions; flag for your medical staff watching the LAI pipeline.

Thin on hard launches this week — two items worth your attention, both on the governance and documentation side.

Ambient scribe data carries a caution for psych documentation. A JAMA Psychiatry cohort study of 20,000+ visits found ambient scribe use was associated with modestly greater documentation of neuropsychiatric symptoms but a lower likelihood of a depression-related intervention or diagnostic code.

Implication: More captured text is not more clinical action — if you’re piloting ambient documentation at intake, audit whether it’s improving or diluting downstream coding and follow-through.

A governance framework lands for BH executives deploying AI. Core Solutions and OPEN MINDS released the Beyond Ambient white paper arguing that organizations are adopting AI faster than they are governing it, with consequences showing up in documentation, compliance exposure, and clinician trust.

Implication: If you’re past pilot and into rollout, the governance gap is your liability surface. (Companion webinar June 18 — see watch list.)

Limited fresh hard data this cycle; the structural picture and one federal lever are what’s actionable.

The demand-supply gap keeps widening. HRSA modeling projects behavioral health service demand rising 49% through 2033 while workforce supply grows only 11%, with the adult psychiatrist shortage reaching into the tens of thousands under elevated-need scenarios.

Implication: Nothing here changes your near-term staffing math, but it’s the backdrop for every retention dollar — psychiatrist vacancy duration isn’t a cyclical problem you wait out.

This week’s only federal workforce lever is the SAMHSA cycle. The $40M announced June 11 explicitly includes strengthening the behavioral health workforce among its grant aims.

Implication: If you have a workforce-development or training-pipeline program, this is the open door this month.

•      June 18 — OPEN MINDS / Core Solutions Beyond Ambient AI governance webinar, 1:00pm EDT. Direct relevance if you’re building an AI policy.

•      June 29 — DOJ begins proceedings on broader reclassification of marijuana (following the Schedule I→III shift for medical/research use). Watch SUD-program implications.

•      June 30 — Colorado SB25-042: DPS, with the BHA, must report on crisis-response resources and reimbursement gaps across the continuum.

•      June 30 — Colorado data-reporting transition: current CCAR/DACODS submission processes hold until June 30 ahead of the FY27 CO-BHRM model. Confirm your reporting team is ready.

•      July 13 — SAMHSA BH-CSP NOFO (SM-26-023) application deadline.

•      August 2026 — CMS IPF PPS FY2027 final rule expected; the comment period closed June 1. The proposal includes a standardized IPF patient assessment instrument and removal of two IPFQR measures — start prepping your QR team now.

The shortage isn’t coming; it’s the floor you’re already standing on. Plan your discharges and your grant cycles accordingly.

Sources

–    HHS/SAMHSA, “$40M in funding opportunities,” June 11, 2026

–    SAMHSA, BH-CSP NOFO (SM-26-023), posted June 11, 2026

–    NACo, summary of CMS Medicaid community engagement IFR (issued June 1, 2026)

–    Colorado HCPF/BHA, “CCBHC Medicaid Demonstration Program,” June 1, 2026

–    Colorado BHA, Technology & Data Systems (CO-BHRM transition), accessed June 2026

–    Colorado General Assembly, SB25-042 (June 30, 2026 deadline)

–    Psychiatric Times, “FDA Approves sNDA of Caplyta for Relapse Prevention,” June 2026

–    Vanda Pharmaceuticals / PR Newswire, Bysanti approval and Q3 2026 availability, Feb 20, 2026

–    Psychiatric Times, “February 2026 Pipeline Review” (Teva TEV-’749 NDA acceptance)

–    JAMA Psychiatry (Castro et al.), ambient scribe documentation cohort study, Jan 21, 2026

–    OPEN MINDS / Core Solutions, Beyond Ambient white paper & June 18 webinar

–    Healing Psychiatry of Florida (HRSA projections summary), May 2026

–    Medscape, “FDA Psychiatry Roundup” (DOJ marijuana June 29 proceedings)

–    CMS / NRC Health, FY2027 IPF PPS proposed rule (comment close June 1, final expected August 2026)

Make sure to subscribe so you don’t miss the next newsletter and you stay informed on the updates shaping behavioral healthcare in Colorado and the nation.